
<!DOCTYPE html>

<html lang="en">
<head>
	<meta charset="utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title></title>
	<link rel="stylesheet" href="css/as.css" type="text/css" />
	<link rel="stylesheet" href="css/animate.css" type="text/css" />
	<script type="text/javascript" src="js/base.js"></script>
	<script type="text/javascript" charset="utf-8">
		
		var ANIMATION = [];
		
	</script>
</head>
<body class="slide-ref">

<div id="popup"> 
<ol>
<li><span>KALETRA [package insert].</span></li>
<li><span>Mills A, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in<br>treatment-naÏve, HIV-1-infected patients: 96-week analysis. <em>AIDS</em>. 2009;23:1679-1688.</span></li>
<li><span>Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus<br>lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. &nbsp;<em>AIDS</em>. <br>
2008;22:1389-1397.</span></li>
<li><span>PREZISTA [package insert]. Raritan, NJ: Tibotec Pharmaceuticals.</span></li>
<li><span>National Heart, Lung, and Blood Institute website. ATP III guidelines at-a-glance quick desk<br>reference. National Cholesterol Education Program. Available at: http://www.nhlbi.nih.gov/<br>guidelines/cholesterol/atglance.pdf. Accessed July 28, 2010.</span></li>
<li><span>Dubé MP, Stein JH, Aberg J, et al. Guidelines for the evaluation and management of dyslipidemia<br>in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy:<br>recommendations of the HIV Medicine Association of the Infectious Disease Society of America<br>and the Adult AIDS Clinical Trial Group. &nbsp;<em>Clin Infect Dis</em>. 2003;37:613-627.</span></li>



</ol>



</div>

</body>
</html>

 
